ESPERION THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.005 USD | +5.53% |
|
+4.97% | -32.94% |
| 25/03 | Esperion Shares Continue Rise After Friday's FDA Approval for Nexlizet, Nexletol | DJ |
| 25/03 | Sector Update: Health Care Stocks Steady Premarket Monday | MT |
| Sales 2024 * | 265M 22.12B | Sales 2025 * | 406M 33.83B | Capitalization | 360M 30.02B |
|---|---|---|---|---|---|
| Net income 2024 * | -69M -5.76B | Net income 2025 * | 60M 5B | EV / Sales 2024 * | 1.36 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.89 x |
| P/E ratio 2024 * |
-4.71
x | P/E ratio 2025 * |
10.2
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
More Fundamentals
* Assessed data
More news
Latest transcript on Esperion Therapeutics, Inc.
More recommendations
More press releases
| 1 day | +5.53% | ||
| 1 week | +4.97% | ||
| Current month | -25.19% | ||
| 1 month | -28.14% | ||
| 3 months | -7.60% | ||
| 6 months | +142.65% | ||
| Current year | -32.94% |
1 week
1.88
2.16
1 month
1.713.40
Current year
1.653.40
1 year
0.703.40
3 years
0.7028.03
5 years
0.7076.98
10 years
0.70120.96
| Managers | Title | Age | Since |
|---|---|---|---|
Sheldon Koenig
CEO | Chief Executive Officer | 58 | 15/20/15 |
| Director of Finance/CFO | 38 | 01/20/01 | |
JoAnne Foody
CTO | Chief Tech/Sci/R&D Officer | 59 | 28/21/28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 52 | 28/22/28 | |
J. Carroll
CHM | Chairman | 74 | 01/22/01 |
Alan Fuhrman
BRD | Director/Board Member | 67 | 16/20/16 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 237 M€ | +2.85% | - | |
| 0.00% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/24/30 | 2.005 | +5.53% | 3 353 484 |
| 26/24/26 | 1.9 | -4.52% | 4,198,930 |
| 25/24/25 | 1.99 | -6.57% | 5,147,052 |
| 24/24/24 | 2.13 | +1.91% | 5,684,029 |
| 23/24/23 | 2.09 | +9.42% | 4,946,560 |
Delayed Quote Nasdaq, April 30, 2024 at 01:02 am IST
More quotes
Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). The Company's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company's NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD). Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine. Its Pipeline product include Next Generation ACLYi.
Sector
Pharmaceuticals
Calendar
07/05/2024
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
1.9
USD
Average target price
7.414
USD
Spread / Average Target
+290.23%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -32.94% | 360M | |
| +25.97% | 661B | |
| +26.74% | 566B | |
| -6.59% | 352B | |
| +18.70% | 332B | |
| +3.62% | 283B | |
| +13.43% | 231B | |
| +4.71% | 200B | |
| -9.53% | 195B | |
| -4.30% | 145B |
- Stock Market
- Equities
- ESPR Stock
